CI
NGNE icon

Cowen Inc’s Neurogene NGNE Stock Holding History

Cowen Inc’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,000
Closed -$53 – 592
2018
Q2 		$53 Buy
+1,000
New +$261K ﹤0.01% 387

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cowen Inc's NGNE Position: Q3 2018 in Review

Cowen Inc sold out of Neurogene (NGNE) in Q3 2018, closing a stake of 1,000 shares — an estimated $53 sold.

Cowen Inc first reported a position in NGNE in Q2 2018 and held it in 1 quarter. The position peaked at $53 in Q2 2018. 45 funds tracked by Wall St. Rank hold NGNE as of Q3 2018.

  • Cowen Inc reported no remaining Neurogene position as of Q3 2018 after selling out during the quarter.
  • Cowen Inc sold 1,000 Neurogene shares in Q3 2018, an estimated $53.
  • Cowen Inc first reported a position in Neurogene in Q2 2018 and held it in 1 quarter.
  • Cowen Inc's Neurogene position peaked at $53 in Q2 2018.
  • 45 funds tracked by Wall St. Rank held Neurogene as of Q3 2018.

Based on Cowen Inc's 13F filing for Q3 2018, filed 13 Nov 2018.